<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161663">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993967</url>
  </required_header>
  <id_info>
    <org_study_id>SNT-III-001-E</org_study_id>
    <nct_id>NCT00993967</nct_id>
  </id_info>
  <brief_title>Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)</brief_title>
  <official_title>A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Extension study of the MICONOS main randomised placebo-controlled trial
      (NCT00905268), and open to those patients completing the main study. The scientific aim of
      this extension study is to monitor safety and tolerability of idebenone over two years in
      patients with Friedreich's Ataxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measures of safety and tolerability: nature and frequency of adverse events (AEs)</measure>
    <time_frame>Month 1, 3, 6, 12, 18 and 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of safety and tolerability: haematological and biochemical laboratory parameters</measure>
    <time_frame>Month 1, 3, 6, 12, 18 and 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of safety and tolerability: physical examinations and vital signs</measure>
    <time_frame>Month 1, 3, 6, 12, 18 and 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of safety and tolerability: electrocardiograms (ECGs)</measure>
    <time_frame>Month 1, 3, 6, 12, 18 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in The International Cooperative Ataxia Rating Scale (ICARS) and Friedreich Ataxia Rating Scale (FARS) scores</measure>
    <time_frame>Baseline, Month 12 and month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Freidreich's Ataxia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idebenone</intervention_name>
    <description>Idebenone 1350 mg/d, patients &lt; or equal 45 kg Idebenone 2250 mg/d, patients &gt; 45 kg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of 52 weeks in study SNT-III-001

          -  Body weight ≥ 25 kg

          -  Negative urine pregnancy test

          -  Eligibility to participate in the present extension study as confirmed by
             investigator

        Exclusion Criteria:

          -  Safety or tolerability issues arising during the course of SNT-III-001 which in the
             opinion of the investigator preclude further treatment with idebenone

          -  Clinically significant abnormalities of haematology or biochemistry including, but
             not limited to, elevations greater than 1.5 times the upper limit of SGOT, SGPT or
             creatinine

          -  Parallel participation in another clinical drug trial

          -  Pregnancy or breast-feeding

          -  Abuse of drugs or alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Wood, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Molecular Neuroscience, Institute of Neurology. The National Hospital, University College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme - Univeristé Libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Salpétrière - INSERM U679, Neurologie et Thérapeutique expérimentale</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik und Ploklinik - Universitätsklimikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik II, Neuropädiatrie und Muskelerkrankungen - Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Neurologische Medizin</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKE Hamburg Neuropädiatrie - Zentrum für Frauen, Kinder und Jugendmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik - Klinikum Grosshadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik und Poliklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 28, 2012</lastchanged_date>
  <firstreceived_date>October 13, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FRDA</keyword>
  <keyword>idebenone</keyword>
  <keyword>FRDA disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Idebenone</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
